A new generation of Australian life sciences innovation will take the stage on the Gold Coast this month, with AusBiotech ...

Recursion Pharmaceuticals Inc. stocks have been trading down by -4.43 percent after AI drug-discovery partnership concerns ...

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its ...

A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European ...

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on ...

Clinical trials are a key driver of biotech stocks. Every new therapy must pass through a series of testing, Phase 1, Phase 2 ...

PYC Therapeutics shares fell nearly 8% amid heightened volatility, with investors focused on upcoming safety and efficacy data for its experimental treatment for inherited kidney disease.

Chinese biotechs can run trials 50–70% faster – our report shows where that speed is paying off, and where the road narrows.

I may have beaten this subject to death over the last month or so, but I cannot resist, and will write about it again.However ...

Hong Kong stocks fell on Wednesday, tracking broader weakness in Asian markets, as oil prices rose,and AI-related and biotech shares led the decline. At the close, Hong Kong benchmark Hang Seng ...

Matchpoint Therapeutics has put together a $150 million Series B to help get MPT-062 into human testing after a $60 million upfront deal with Novartis.

Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ ...